EQS-News: Redcare Pharmacy Q2 2023: While fast sales growth continues unabated at 46%, adj. EBITDA margin improved 5.3pp year over year to 3.2%. Company raises full-year guidance.
Redcare Pharmacy Q2 2023: While fast sales growth continues unabated at 46%, adj.
- Redcare Pharmacy Q2 2023: While fast sales growth continues unabated at 46%, adj.
- Final figures show sales grew 46.2% year over year in Q2 to EUR 420 million (Q2 2022: EUR 287 million).
- Non-Rx sales growth was confirmed at 27% in Q2 to EUR 323 million (Q2 2022: EUR 255 million).
- In Q2 2023, adjusted S&D expenses were 19.3% of sales, or EUR 81.1 million (Q2 2022: 26.3% of sales, or EUR 75.5 million).